Soft Tissue Sarcoma Research
-
Epigenetic Changes Pinpointed as the Cause of Some GISTsPosted:
Scientists may have pinpointed the cause of some gastrointestinal stromal tumors (GISTs), a rare cancer, according to a new NCI-funded study. However, the culprit isn’t a harmful genetic mutation, but another type of genetic change, what are called epigenetic alterations.
-
Immunotherapy Effective in Alveolar Soft Part SarcomaPosted:
People with advanced alveolar soft part sarcoma (ASPS), a rare cancer, appear to benefit from a type of immunotherapy called an immune checkpoint inhibitor, according to results from a small clinical trial.
-
NIH-funded study shows sorafenib improves progression-free survival for patients with rare sarcomasPosted:
Interim results from a clinical trial for patients with desmoid tumors or aggressive fibromatosis (DT/DF) show that the drug sorafenib tosylate (Nexavar) extended progression-free survival compared with a placebo.
-
New Targeted Therapies Show Promise for Treating Advanced GISTPosted:
Two new targeted therapies have shown promise in patients with gastrointestinal stromal tumors (GIST) that have developed resistance to standard therapies.
-
Olaratumab Approved to Treat Advanced Soft Tissue SarcomaPosted:
The Food and Drug Administration (FDA) has granted accelerated approval to olaratumab (Lartruvo®) for the treatment of some patients with soft tissue sarcoma.
-
FDA Approves Eribulin Mesylate for Advanced LiposarcomaPosted:
The FDA has approved eribulin mesylate for patients with liposarcoma whose cancers are advanced or cannot be removed by surgery and are no longer responding to anthracycline-based chemotherapy.
-
FDA Approves Trabectedin to Treat Two Types of Soft Tissue SarcomaPosted:
The FDA has approved trabectedin for patients with advanced liposarcoma and leiomyosarcoma whose cancer has progressed after prior treatment.
-
In Mice, New Drug Conjugate Suggests Promise for Hard-to-Treat Pediatric CancersPosted:
Findings from a study in mice suggests that a new type of drug conjugate may have potential as a treatment for two cancers that are often diagnosed in children.
-
A key molecular defect in a childhood gastrointestinal tumor may have important diagnostic implicationsPosted:
NCI scientists have identified a key molecular defect in a tumor in children known as gastrointestinal stromal tumor, or GIST, that may have important diagnostic implications.
-
NIH scientists map genetic changes that drive tumors in a common pediatric soft-tissue cancerPosted:
Scientists have mapped the genetic changes that drive tumors in rhabdomyosarcoma, a pediatric soft-tissue cancer, and found that the disease is characterized by two distinct genotypes. The genetic alterations identified in this malignancy could be useful in developing targeted diagnostic tools and treatments for children with the disease.
-
New Targeted Treatment May Slow Disease in Patients with Advanced GISTPosted:
A new oral drug, regorafenib (Stivarga®), may delay the progression of advanced gastrointestinal stromal tumors (GIST) that are resistant to treatment, according to results from an international clinical trial published November 22, 2012, in The Lancet.